 |
|
Medical Crossfire PodPearls feature brief exchanges between a moderator and faculty members on important topics of interest to the practicing clinician. PodPearls CME-certified audio files can be listened to online or downloaded to an MP3 player. This format brings the clinical insights physicians have come to expect from Medical Crossfire to the busy clinician who needs to stay up-to-date on the implications of current knowledge on patient care.
A complimentary CME-certified activity
Educational Overview
The epidemic of overweight and obesity in the US has resulted in a marked increase in the prevalence of diabetes and the metabolic syndrome. Although we have made great strides in addressing traditional cardiovascular (CV) risk factors, patients with cardiometabolic risk—particularly those with excess central adiposity—still experience a high rate of major CV events. This considerable “residual” risk has left researchers and clinicians searching for new therapeutic approaches through which more favorable patient outcomes might be achieved.
This Pod Pearl series will allow an examination of the metabolic syndrome, specifically detailing its utility as a clinical construct and exploring the implications of the clustering of cardiometabolic risk factors to their underlying pathophysiology. In addition, the nature of residual cardiometabolic risk will be addressed, as will current and emerging clinical strategies for better managing such risk. Finally, specific approaches to directly addressing excess body weight through lifestyle changes, approved and emerging medical therapies, and bariatric surgery, will be discussed.
Target Audience
This educational activity is designed for cardiologists and other health care professionals interested in or involved with the management of patients cardiometabolic risk.
Method of Instruction
Participants should read the learning objectives and listen to the activity in its entirety. After reviewing the activity, print out and mail or fax the evaluation and you will receive a letter of credit awarding AMA PRA Category 1 Credit(s)TM three to four weeks after receipt of the evaluation.
Estimated time to complete this activity as designed is 0.25 hour.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Media Communications and Liberty Communications Network.
Medical Media Communications, Department of CME, is accredited by the ACCME to provide CME for physicians.
Medical Media Communications designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s).TM Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Medical Education credit will be awarded free of charge via mail within 4 weeks following the activity to physicians who review the program for its duration and return a successfully completed posttest and evaluation form to: Medical Media Communications, CME Department, 6133 North River Road, Suite 830, Rosemont, IL 60018.
Program Panel
Panelists
 |
|
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Associate Director, Cleveland Clinic Cardiovascular Coordinating Center
Staff, Cardiac, Peripheral, and Carotid Intervention
Associate Professor of Medicine, Department of Cardiovascular Medicine
Cleveland Clinic Foundation
Cleveland, Ohio |
|
|
|
 |
|
Darren K. McGuire, MD, MHSc
Assistant Professor, Internal Medicine
Director, Parkland Hospital and Health Systems Outpatient Cardiology Clinics
Associate, Donald W. Reynolds Cardiovascular Clinical Research Center
University of Texas Southwestern Medical Center at Dallas;
Internal Medicine
Southwestern Medical School
Dallas, Texas |
|
|
|
 |
|
Jorge Plutzky, MD
Director, Vascular Disease Prevention Program
Brigham and Women’s Hospital;
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts |
|
|
|
| Moderator |
|
|
 |
|
Christie M. Ballantyne, MD
Professor of Medicine
Chief, Section of Atherosclerosis and Vascular Medicine
Department of Medicine
Baylor College of Medicine;
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center and Baylor College of Medicine
Houston, Texas
|
Disclosure Declarations
In accordance with the disclosure policies of Medical Media Communications and Liberty Communications Network, and to conform with ACCME and FDA guidelines, all program faculty are required to disclose to the activity participants: 1) the existence of any financial interest or other relationships with the manufacturers of any commercial products/devices, or providers of commercial services, that relate to the content of their presentation/material, or the commercial contributors of this activity, that could be perceived as a real or apparent conflict of interest; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Faculty Disclosure Delcarations
Dr. Ballantyne has received grant/research support from AstraZeneca Pharmaceuticals, Gene Logic, GlaxoSmithKline, Kos Pharmaceuticals, Merck & Co., Novartis Pharmaceuticals Corp., Pfizer, Roche, Sankyo Pharma, Sanofi-Synthelabo, Schering-Plough Pharmaceuticals, and Takeda Pharmaceuticals North America; has been a consultant for AstraZeneca Pharmaceuticals, diaDexus, Merck & Co., Novartis Pharmaceuticals Corp., Pfizer, Reliant Pharmaceuticals, Sanofi-Synthelabo, and Schering-Plough Pharmaceuticals; and has served on the speakers’ bureaus of AstraZeneca Pharmaceuticals, Kos Pharmaceuticals, Merck & Co., Pfizer, Reliant Pharmaceuticals, and Schering-Plough Pharmaceuticals.
Dr. Bhatt has been a consultant for AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eisai Pharmaceuticals, Eli Lilly and Co., GlaxoSmithKline Pharmaceuticals, Millennium Pharmaceuticals, Par Pharmaceutical, PDL BioPharma, sanofi-aventis, Schering–Plough Pharmaceuticals, and The Medicine Company; and has served as a paid speaker for Bristol-Myers Squibb, sanofi-aventis, and The Medicine Company.
Dr. McGuire has received grant/research support from GlaxoSmithKline Pharmaceuticals; has been a consultant for Tethys Biosciences; and has served as a paid speaker for Pfizer and Takeda Pharmaceuticals North America.
Dr. Plutzky has received grant/research support from Takeda Pharmaceuticals North America; has been a consultant for AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals, Laboratories Fournier, Merck & Co., Novo Nordisk, ONO Pharmaceutical Co., Pfizer, sanofi-aventis, and Takeda Pharmaceuticals North America; and has served on the speakers’ bureaus of AstraZeneca Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, sanofi-aventis, and Takeda Pharmaceuticals North America.
Off-Label Usage Disclosure
Please note that this activity contains discussions of unlabeled uses of FDA-approved pharmaceutical products, as well as discussions of investigational products not yet approved by the FDA. Please refer to the official prescribing information for approved indications, contraindications and warnings.
Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of sanofi-aventis, any other manufacturer of pharmaceuticals, Medical Media Communications, or Liberty Communications Network.
It should be noted that the recommendations made herein, with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating panelists. The drug selection and dosage information provided in this activity are believed to be accurate. However, the participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.
Copyright © 2007 by Liberty Communications Network. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems without permission in writing from Liberty Communications Network.
 |
|
Topic 1:
The Metabolic Syndrome
Insights and Applications
|
At the conclusion of the activity, participants should be able to:
|
| • |
Discuss the pathological processes underlying the metabolic syndrome, including the range of
negative effects of intra-abdominal adiposity.
|
| • |
Understand the utility of the metabolic syndrome as a clinical construct.
|
| • |
Describe the implications of the metabolic syndrome when assessing and managing patients’ short- and long-term cardiometabolic risk.
|
|
|
Topic 2:
Residual Cardiometabolic Risk in Patients Treated to Guideline-Defined Goals
|
At the conclusion of the activity, participants should be able to:
|
| • |
Better appreciate the considerable cardiovascular morbidity and mortality of patients whose traditional
cardiovascular risk factors are treated to goal.
|
| • |
Discuss the importance of non-traditional cardiometabolic risk factors to a patient’s overall risk profile.
|
| • |
Describe the role of central adiposity as an upstream contributor to multiple cardiometabolic risk factors, and the
importance of addressing it appropriately.
|
|
|
Topic 3:
Managing Cardiometabolic Risk
The Role of Pharmacotherapy in the Treatment of Overweight and Obesity
|
At the conclusion of the activity, participants should be able to:
|
| • |
Describe the current epidemic of overweight/obesity and its impact on cardiometabolic risk.
|
| • |
Understand the importance of addressing overweight and obesity when managing patients with cardiometabolic risk, through both lifestyle and pharmacological means.
|
| • |
Discuss the potential clinical benefits of emerging pharmacotherapies that directly target
central adiposity.
|
| For questions about downloading, please visit our FAQ section here |
| Jointly Sponsored by ..... |
  |
| This activity is supported by an educational grant from sanofi-aventis. |
 |
|
